Summary
97.48 0.94(0.97%)11/20/2024
Merck & Co Inc (MRK)
MRK reported last earnings on 2024-10-31 after the market. An EPS of $1.57 was observed compared to an estimated EPS of $1.5, resulting in a surprise value of $0.07. A revenue of $16,657 million was observed compared to an estimated revenue of $16,474 million, resulting in a surprise value of $183 Million.
Merck & Co Inc (MRK)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.12 | -1.04 | -8.32 | -15.34 | -25.58 | -5.07 | 32.24 | 137,520.18 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Earnings
Fundamental Ratings
| Category | Rating |
| Main Rating | B+ |
| Recommended Rating | Neutral |
| DCF | Buy |
| ROE | Strong Buy |
| ROA | Strong Buy |
| Debt/Equity | Strong Sell |
| P/E | Sell |
| P/B | Strong Sell |
| Trading Data | ||
| Close | 97.48 | |
| Open | 96.98 | |
| High | 98.84 | |
| Low | 96.66 | |
| Volume | 6,283,691 | |
| Change | 1.08 | |
| Change % | 1.12 | |
| Avg Volume (20 Days) | 7,824,986 | |
| Volume/Avg Volume (20 Days) Ratio | 0.80 | |
| 52 Week Range | 94.48 - 134.63 | |
| Price vs 52 Week High | -27.60% | |
| Price vs 52 Week Low | 3.17% | |
| Range | 0.51 | |
| Gap Up/Down | -0.57 | |
Fundamentals | ||
| Market Capitalization (Mln) | 268,386 | |
| EBIDTA | 21,211,000,832 | |
| PE Ratio | 144.5111 | |
| PEG Ratio | 0.1008 | |
| WallStreet Target Price | 141.42 | |
| Book Value | 15.9370 | |
| Earnings Per Share | 0.9000 | |
| EPS Estimate Current Quarter | 1.8700 | |
| EPS Estimate Next Quarter | 2.1600 | |
| EPS Estimate Current Year | 8.6600 | |
| EPS Estimate Next Year | 9.9900 | |
| Diluted EPS (TTM) | 0.9000 | |
| Revenues | ||
| Profit Marging | 0.0376 | |
| Operating Marging (TTM) | 0.4247 | |
| Return on asset (TTM) | 0.1026 | |
| Return on equity (TTM) | 0.0531 | |
| Revenue TTM | 61,403,000,832 | |
| Revenue per share TTM | 24.2150 | |
| Quarterly Revenue Growth (YOY) | 0.0890 | |
| Quarterly Earnings Growth (YOY) | 0.6850 | |
| Gross Profit (TTM) | 42,077,000,000 | |
| Dividends | ||
| Dividend Share | 2.9600 | |
| Dividend Yield | 0.0237 | |
| Valuations | ||
| Trailing PE | 144.5111 | |
| Forward PE | 14.6843 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 8.4751 | |
| Revenue Enterprise Value | 5.7634 | |
| EBITDA Enterprise Value | 50.1614 | |
| Shares | ||
| Shares Outstanding | 2,532,809,984 | |
| Shares Float | 2,527,943,319 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.05 | |
| Institutions (%) | 77.99 | |
11/19 12:22 EST - businesswire.com
Merck Announces First-Quarter 2025 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2025 Dividend.
Merck Announces First-Quarter 2025 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2025 Dividend.
11/19 11:28 EST - seekingalpha.com
Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
In recent weeks, financial participants have remained pessimistic about Merck's development prospects, partly due to the nomination of Robert F. Kennedy Jr. as head of HHS. However, I believe Mr. Market overreacted to this news, given the strong performance of Merck's oncology franchise in recent...
Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
In recent weeks, financial participants have remained pessimistic about Merck's development prospects, partly due to the nomination of Robert F. Kennedy Jr. as head of HHS. However, I believe Mr. Market overreacted to this news, given the strong performance of Merck's oncology franchise in recent...
11/19 10:49 EST - barrons.com
Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.
The company has been preparing for the 2028 expiration of its patents protecting Keytruda.
Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.
The company has been preparing for the 2028 expiration of its patents protecting Keytruda.
11/19 08:11 EST - youtube.com
Injectable version of cancer drug Keytruda works as well as current IV form: Merck
CNBC's Angelica Peebles reports on news from Merck.
Injectable version of cancer drug Keytruda works as well as current IV form: Merck
CNBC's Angelica Peebles reports on news from Merck.
11/19 07:54 EST - marketwatch.com
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
The news may help Merck retain sales of Keytruda, which is the world's best-selling drug.
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
The news may help Merck retain sales of Keytruda, which is the world's best-selling drug.
11/19 06:49 EST - reuters.com
Merck says Keytruda injection on par with approved IV version in trial
Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more accessible and easier to administer.
Merck says Keytruda injection on par with approved IV version in trial
Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more accessible and easier to administer.
11/19 06:45 EST - businesswire.com
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab,...
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab,...
11/18 11:35 EST - zacks.com
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.
11/18 02:23 EST - seekingalpha.com
Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 10 companies to announce their annual increases in the second half of November, including modest increases from Merck and a 10%+ increase from...
Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 10 companies to announce their annual increases in the second half of November, including modest increases from Merck and a 10%+ increase from...
11/15 22:03 EST - forbes.com
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.
11/15 15:40 EST - zacks.com
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
11/15 11:21 EST - benzinga.com
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
11/15 07:15 EST - businesswire.com
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA®...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA®...
11/14 18:54 EST - seekingalpha.com
100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys
Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators, including workplace diversity and greenhouse-gas emissions. Eight of 78 dividend-paying sustainable companies offer dividends exceeding their share prices, signalling potential buy...
100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys
Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators, including workplace diversity and greenhouse-gas emissions. Eight of 78 dividend-paying sustainable companies offer dividends exceeding their share prices, signalling potential buy...
11/14 09:17 EST - seekingalpha.com
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's stock is undervalued, trading at less than 4x expected 2024 revenues, despite strong revenue growth from Keytruda and other drugs. Keytruda's revenue is projected to increase by 70% from 2024 to 2032. Declining Gardasil sales in China and competition from Summit Therapeutics and Roche's...
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's stock is undervalued, trading at less than 4x expected 2024 revenues, despite strong revenue growth from Keytruda and other drugs. Keytruda's revenue is projected to increase by 70% from 2024 to 2032. Declining Gardasil sales in China and competition from Summit Therapeutics and Roche's...
11/14 07:15 EST - businesswire.com
Merck to Participate in the Jefferies London Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies London Healthcare Conference.
Merck to Participate in the Jefferies London Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies London Healthcare Conference.
11/14 07:02 EST - reuters.com
Merck signs $3.3 bln deal for experimental cancer drug
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
Merck signs $3.3 bln deal for experimental cancer drug
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
11/14 06:45 EST - businesswire.com
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and...
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and...
11/13 16:03 EST - seekingalpha.com
Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) UBS Global Healthcare Conference November 13, 2024 12:30 PM ET Company Participants Jannie Oosthuizen - President of Human Health of the U.S. Joerg Koglin - SVP of Clinical Research Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think we're...
Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) UBS Global Healthcare Conference November 13, 2024 12:30 PM ET Company Participants Jannie Oosthuizen - President of Human Health of the U.S. Joerg Koglin - SVP of Clinical Research Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think we're...